Other attempts to identify such a specific treatment for Alzheimer's have failed, according to Dr.Michelle Nicolle, the lead researcher. As per her claim "current treatments only treat the symptoms while the underlying disease is still progressing and so recent research efforts are focusing on stopping disease progression instead of symptomatic treatment".
The researchers' findings suggest that the compound BQCA, could alter the progression of disease in mice and ultimately hold importance for humans as well.
BQCA activates a specific neurotransmitter receptor in the brain called the M1 muscarinic acetylcholine receptor. M1 receptors have been the focus of research into treatment of Alzheimer's disease because they affect the part of the brain that stimulates the memory and learning functions the disease inhibits. Until now, scientists have not found a treatment selective enough to activate the receptors without producing side effects such as nausea, vomiting and increased frequency of urination. As per the claim, BCQA is specific and BQCA also seemed to inhibit production of amyloid beta, one of the markers of Alzheimer's disease in the brain - perhaps key to the compound's potential for slowing the progression of the disease. Though detailed studies are still to be established its an interesting research. I found an interesting article in the same lines, those interested can read.
Ref : http://www.wfubmc.edu/News-Media-Resources/
